Advertisement
Advertisement
BRTX
BioRestorative Therapies, Inc. Common Stock (NV)
0.31
USDSponsored
+0.01
+5.08%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
0.31
0.00
-0.32%
BRTX Earnings Reports
Positive Surprise Ratio
BRTX beat 12 of 15 last estimates.
80%
Next Report
Today BMO
Date of Next Report
Mar 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$153.00K
/-$0.37
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
+253.35%
/+85.00%
BioRestorative Therapies, Inc. Common Stock (NV) earnings per share and revenue
On --, BRTX reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.37 USD, with revenue projected to reach 153.00 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were BioRestorative Therapies, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q-- --?
For Q-- --, BioRestorative Therapies, Inc. Common Stock (NV) reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to BioRestorative Therapies, Inc. Common Stock (NV)'s Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is BioRestorative Therapies, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for Mar 26, 2026.
What are the forecasts for BioRestorative Therapies, Inc. Common Stock (NV)'s next earnings report?
Based on 4
analysts, BioRestorative Therapies, Inc. Common Stock (NV) is expected to report EPS of -$0.37 and revenue of $153.00K for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement